JP2002154989A - Ophthalmic composition and composition having improved retention of medicine in biological mucosa - Google Patents

Abstract

PROBLEM TO BE SOLVED: To obtain a composition having excellent retention of medicine in a biological mucosa, especially an ophthalmic composition. SOLUTION: This composition is characterized in that the composition comprises (A) a medicine, (B) preferably two or more kinds of water-soluble polymer compounds selected from cellulosic polymer compounds and polyvinyl alcohols having >=78 mol% degree of saponification and (C) if required, a viscosity-reducing agent and has 1-20 mPas viscosity in use.

Description

DETAILED DESCRIPTION OF THE INVENTION

[0001]

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an ophthalmic composition having good retentivity to the ocular mucosa and a composition for improving the mucosal retentivity of a drug.

[0002]

2. Description of the Related Art Heretofore, there has been known a technique for improving the retentivity of a drug at a physical location by increasing the viscosity of a preparation. Ointment-type preparations and the like are also known for pharmaceutical compositions applied to the eye, but they are extremely sticky and have poor usability. In addition, the solution type eye drops having high viscosity have drawbacks such as difficulty in dropping the composition from an eye drop container having a relatively small dropping port, in addition to poor feeling in use. In ophthalmic treatment, as a treatment method to improve the effectiveness of the drug,
There is a method to improve local retention by combining an ophthalmic composition and a soft contact lens to increase the effectiveness of treatment.However, this method requires long-time wearing of a contact lens, so there is an adverse effect such as occurrence of fungi, and the cost is low. high. Also, JP-A-8-99867 discloses an ophthalmic vehicle that increases the corneal penetration of an active substance, which is an oil-in-water nanoemulsion containing oil, a nonionic surfactant, benzalkonium chloride, and a biologically active substance. However, there are problems such as the productivity and stability of the emulsion. JP 62
No. 181228 discloses a pharmaceutical composition containing a polysaccharide that gels due to an increase in ionic strength (tears), but the drug retention may not always be sufficient.

[0003]

SUMMARY OF THE INVENTION Accordingly, an object of the present invention is to provide an ophthalmic composition which is easy to produce, has excellent drug retention, and has good usability.

[0004]

Means for Solving the Problems The present inventors have studied to solve the above problems, and by using a specific polymer compound, the polymer compound interacts with mucin existing on the surface of the eye mucosa. It has been found that by acting, the retention of a drug coexisting in the preparation on the mucous membrane is improved, and the present invention has been completed. Furthermore, a specific polymer compound is
It has been found that when more than one kind is used, a drastic improvement in the retention of a drug can be obtained, and an ophthalmic composition having excellent drug efficacy can be obtained, and the present invention has been completed.

That is, the present invention provides (A) a drug (B) a cellulosic polymer compound, and a saponification degree of 78 mol.
% Or more of two or more water-soluble polymer compounds selected from polyvinyl alcohol (C) containing a viscosity reducing agent if necessary and having a viscosity of 1 to 20 when used.
An ophthalmic composition characterized by mPas is provided.

The present invention also provides a composition for improving the retention of a drug on a living mucosa, comprising a cellulosic polymer compound and / or polyvinyl alcohol having a saponification degree of 78 mol% or more. . Hereinafter, the present invention will be described in detail.

[0007]

BEST MODE FOR CARRYING OUT THE INVENTION The drug which is the component (A) in the present invention includes drugs described in Japanese Pharmacopoeia, United States Pharmacopeia, British Pharmacopoeia, local regulations and substances described as nutritional components. In particular, drugs that stay and act on the cornea and conjunctiva, such as antiallergic agents, decongestants, antiinflammatory agents, and vitamins, are preferable because their effectiveness is improved.

[0008] Anti-allergic agents include sodium cromoglycate and chlorpheniramine maleate, decongestants include naphazoline hydrochloride and tetrahydrozoline hydrochloride, anti-inflammatory agents include dipotassium glycyrrhizinate, sodium azulene sulfonate, and vitamins. Vitamin A, vitamin E, pyridoxine hydrochloride, sodium flavin adenine dinucleotide, cyanocoveramine, and panthenol are particularly preferred.

[0009] The compounding amount of the drug can be appropriately selected depending on the type. For example, suitable amounts of typical drugs in ophthalmic compositions are shown below. Sodium cromoglycate can be usually added in an amount of 0.05 to 10.0 w / v%, preferably 0.1 to 5.0 w / v%. Chlorpheniramine maleate is usually 0.00
5 to 1.0 w / v% can be blended, preferably in the range of 0.01 to 0.1 w / v%. Naphazoline hydrochloride can be usually added in an amount of 0.0001 to 0.1 w / v%, preferably in a range of 0.001 to 1.01 w / v%. Tetrahydrozoline hydrochloride is usually 0.00
The amount can be 1 to 1.0 w / v%, preferably in the range of 0.01 to 0.1 w / v%.

[0010] Dipotassium glycyrrhizinate is usually used in an amount of 0.
It can be blended in the range of 0.5 to 3.0 w / v%, and preferably in the range of 0.1 to 2.0 w / v%. Sodium azulene sulfonate is usually 0.001-1.0 w / v%,
Preferably it is in the range of 0.005 to 0.1 w / v%.
In the case of retinol palmitate, which is a vitamin A, usually 0.001 to 0.2 W / V% in the composition, that is, 1%
000-360,000 international units / 100 ml (hereinafter I.I.
U. / 100 ml), preferably 0.01 to 0.1 W / V%, that is, 10,000 to 1
80000I. U. / 100 ml. In the case of tocopherol acetate of vitamin Es (for example, d-α tocopherol acetate), usually 0.001 to 1.0 w /
v%, preferably 0.01 to 0.3%
w / v% range.

Pyridoxine hydrochloride is usually used in an amount of 0.005 to 0.005.
2.0 w / v%, preferably 0.0
It is in the range of 1 to 1.0 w / v%. Flavin adenine dinucleotide sodium is usually 0.001-1.0 w
/ V%, preferably from 0.01 to 0.1%.
It is in the range of 1 w / v%. Cyanocobalamin is usually
0.001 to 1.0 w / v% can be blended, preferably in the range of 0.005 to 0.1 w / v%. Panthenol can be usually added in an amount of 0.001 to 2.0 w / v%, preferably in the range of 0.01 to 1.0 w / v%.

The polymer compound (B) of the present invention is a cellulosic polymer compound having a saponification degree of 78 mol%.
A water-soluble polymer compound selected from the above polyvinyl alcohols.

As the cellulosic polymer compound, crystalline cellulose, methylcellulose, ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylethylcellulose,
Hydroxyethyl cellulose, carboxymethyl cellulose, hydroxyethyl methyl cellulose and the like can be mentioned.

Among the above, a cellulose ether in which a part of the hydrogen atom of the hydroxyl group is substituted with a methyl group, an ethyl group, a hydroxypropyl group or a hydroxyethyl group is preferred. Particularly preferred cellulosic polymer compounds are methylcellulose and hydroxypropylmethylcellulose. These have a particularly strong interaction force with mucin,
The effectiveness of the drug is significantly improved. The preferred alkoxyl group substitution rate of the hydroxyl group of the cellulose ether is 10 to 4
5%, especially 15-45% is preferred. Further, the interaction force of the cellulosic polymer compound to mucin is particularly effective when the weight average molecular weight is 5 × 10 ⁴ or more,
Further, 5 × 10 ⁴ to 1 × 10 ⁶ , 5 × 10 ^{4 to} 5 × 10
⁵ is preferred.

The content of the cellulosic polymer compound is preferably 0.01 to 10 W / V% (mass / volume%, hereinafter the same) in the composition, particularly preferably 0.05 to 5 W / V.
%.

The polyvinyl alcohol used in the present invention has a degree of saponification of 78 mol% or more, preferably 78 mol%.
９６96 mol%, particularly preferably 85-90 mol%. The molecular weight of the preferred polyvinyl alcohol is 10,000 to 200,000, preferably 20,000 to 150,000. The content of the polyvinyl alcohol is preferably 0.02 to 20 w / v% in the composition, more preferably 0.05 to 1 w / v%.
0 w / v%, particularly preferably 0.1 to 10 w / v%.

In the present invention, the content of the polymer compound (B) is preferably 0.02 to 20 W / V%,
More preferably, it is 0.05 to 10 W / V%, particularly preferably 0.1 to 10 W / V%.

By using two or more of the polymer compounds of the present invention, remarkable drug mucosa retention can be obtained. These combinations may use two types of cellulosic polymers or a combination of cellulosic polymers and polyvinyl alcohol, but a preferable combination of water-soluble polymer compounds is one or more types of cellulosic polymers. And polyvinyl alcohol. The preferred content ratio of these is: cellulosic polymer: polyvinyl alcohol = 1: 1000 to 200: 1, more preferably 1:20.
Mixtures in the range from 0 to 50: 1, particularly preferably from 1: 100 to 30: 1.

Examples of the viscosity reducing agent which is the component (C) of the present invention include surfactants and alcohols having 2 to 8 carbon atoms. The surfactant is preferably a nonionic surfactant, and includes polyoxyethylene fatty acid ester, polyoxyethylene sorbitan higher fatty acid ester, polyoxyethylene polyoxypropylene fatty acid ester, and more specifically, polyoxyethylene cured. Castor oil 60 (for example, HCO-60 manufactured by Nikko Chemicals Co., Ltd.)
Polyoxyethylene (20) sorbitan monooleate (for example, TO-10 manufactured by Nikko Chemicals Co., Ltd.), polyoxyethylene (196) polyoxypropylene (6)
7) Glycol (for example, Pronic F127 manufactured by Asahi Denka Kogyo KK), polyoxyethylene (160) polyoxypropylene (30) glycol (for example, Pronic F68 manufactured by Asahi Denka Kogyo KK) and the like. In particular, polyoxyethylene hydrogenated castor oil 60 is preferable because it gives a good feeling of use when administered to a living body.

The concentration of the surfactant is 0.0001 W / V
% To 10 W / V% or less, preferably 0.00%
It is in the range of 1 W / V% or more and 10 W / V%. Within this concentration range, an increase in the viscosity of the nonionic water-soluble polymer in the preparation can be satisfactorily suppressed, and the usability is good without any unpleasant feeling such as stickiness.

Examples of the alcohol having 2 to 8 carbon atoms include ethanol, glycerin, propylene glycol, dipropylene glycol, monoethanolamine, and phenylethyl alcohol. The above alcohols can be contained in the composition in the range of 0.001 to 10 W / V%.

If necessary, the above-mentioned thickener is added to the ophthalmic composition of the present invention, and the viscosity at 20 ° C. of the composition is adjusted to 1 mPas.
２０20 mPas, preferably 1 mPas〜15 mPas
Adjust so that With the viscosity in this range, the ophthalmic solution containing the polymer compound of the present invention has good ophthalmic properties (easy to come out of an ophthalmic container), and has no stickiness and a good feeling in use. The content of the component (C) with respect to the component (B) is as follows:
(C) / (B) = 0.0001 to 10, preferably 0.
It is desirable to adjust the viscosity within the range of 001 to 1.

In order to further enhance the effects of the present invention, the composition preferably contains (D) a buffer. Examples of the buffer include inorganic acids and / or salts thereof that generate divalent or higher-valent ions, and amino compounds such as ε-aminocaproic acid, tromethamol, and ethanolamine. As the inorganic acid and / or its salt, boric acid, borax, sodium hydrogen phosphate, sodium dihydrogen phosphate, crystalline sodium phosphate, monopotassium phosphate, potassium dihydrogen phosphate,
Examples thereof include citric acid, sodium citrate, sodium dihydrogen citrate, sodium carbonate, and sodium hydrogen carbonate. Among these, inorganic acids and / or salts thereof and trometamol are particularly preferred because they have a high effect of enhancing the interaction force of the polymer with mucin, and the effectiveness is enhanced. The amount of the buffer in the ophthalmic composition of the present invention is 0.01 W / V% or more and 10% or less.
W / V% or less is preferable.

The effect of the composition of the present invention is to exert a specific action on mucin present in the mucosa of a living body by using a specific polymer compound, especially by using two or more kinds in combination.
It dramatically improves the retention of coexisting drugs. The compositions of the present invention are particularly useful as ophthalmic compositions.
As an ophthalmic composition, the specific polymer compound of the present invention and a viscosity reducing agent, preferably a surfactant, are adjusted to an appropriate viscosity by coexistence. Since the increase in viscosity due to the entanglement of the high molecular compound therein is suppressed, it is easy to instill eye drops, and it efficiently contacts the mucous membrane of the eye. Then, when the concentration is lower than the concentration effective as a thickener diluted by tears, the specific polymer compound in the composition specifically interacts with mucin, and the local viscosity at the target site increases. It is thought that the local retention of the drug in the substance is increased, and the efficacy is improved. Furthermore, by including a buffer in the composition, the interaction of the polymer compound with mucin is further enhanced.

[0025] In addition to the above, the ophthalmic composition of the present invention may contain components usually added to the ophthalmic composition within a range not to impair the effects of the present invention. Preservatives such as potassium sorbate, paraben, benzalkonium chloride, chlorhexidine gluconate, chlorobutanol, tetrasodium ethylenediaminetetraacetate,
Sodium edetate, sodium bisulfite, sodium sulfite, sodium thiosulfate, sodium pyrosulfite, sodium metabisulfite, stabilizers such as dibutylhydroxytoluene and ascorbic acid, menthol, camphor, borneol, peppermint oil, bergamot oil, eucalyptus oil , Chilled oil such as fennel oil, cool mint, solubilizing agents such as polyethylene glycol (carbon number 9 or more), tonicity agents such as sodium chloride, potassium chloride, glucose, etc., pH adjusters such as sodium hydroxide and hydrochloric acid And the like. The ophthalmic composition of the present invention is adjusted to pH 5.0 to 8.0 and osmotic pressure 200 to 400.

The drug retention improving composition of the present invention is particularly preferably applied to the ocular mucosa, but can be used for other living mucous membranes. The site of application is a living mucosa where mucin is present, and can be preferably used for drug administration to the eyes (cornea, conjunctiva), nose, stomach, small intestine, large intestine, and genital area. In particular, it can be preferably used as an ophthalmic composition containing a drug, particularly as an eye drop or a nasal drop.

Hereinafter, the present invention will be described in more detail by way of examples to clarify the effects of the present invention. However, this is merely an example, and the present invention is not limited to these examples.

[0028]

EXAMPLES Ophthalmic compositions shown in Table 1 were prepared according to a conventional method (a sodium hydroxide or hydrochloric acid was used as a pH adjuster), and the retention of the drug on the ocular mucosa was evaluated by the following method.

Test 1 (Evaluation of the interaction of the ophthalmic composition with mucin) Solution A in which the test solution was mixed with an equal amount of a 3% by mass mucin solution, and Solution B in which the test solution was mixed with an equal amount of water Two kinds of evaluation liquids were prepared, and the viscosity behaviors of both were compared. The measurement was performed at 35 ° C. to simulate the environment in which the ophthalmic composition acts on the ocular mucosa (E-type viscometer). The viscosity ratio of solution A to solution B was used as an index of the specific interaction with mucin, that is, the local thickening effect at the target biological site. In the evaluation, the value of the viscosity of the liquid A / the viscosity of the liquid B was calculated and evaluated according to the following criteria. Score (viscosity of solution A) / (viscosity of solution B) 5 points 2.00 or more 4 points 1.75 or more to less than 2.00 3 points 1.50 or more to less than 1.75 2 points 1.25 or more to 1 Less than 50 1 point Less than 1.25

Test 2 (Evaluation of Retention of Ophthalmic Composition in Rabbit Eye Conjunctival Sac) The retention of sodium cromoglycate in the ocular conjunctival sac of rabbits was evaluated. Apply test solution to separate eyes of rabbit
Each μL was instilled, and 10 minutes later, tears were collected by a capillary. Then, the concentration of the drug contained in the tears was measured by high performance liquid chromatography, and the retention of sodium cromoglycate in the conjunctival sac was compared. The test was performed three times or more, and the measured values were averaged.

[0031]

[Table 1]

From Table 1, it was confirmed that the composition containing the specific polymer compound of the present invention improved the mucosal retention of the drug. Further, a composition containing two or more types has particularly good drug retention properties. In addition, a correlation was observed between the viscosity behavior due to mixing with the mucin solution in Test 1 and the evaluation of drug retention in Test 2. In the following Examples, only Test Example 1 is shown as a simple evaluation of the retention.

[0033]

[Table 2] Further, eye drops of Tables 3 to 5 were prepared, and the feeling of use was evaluated by Test 1 and the following method.

Test 3 (Evaluation of feeling of use of eye drops) Five test samples were instilled into healthy men and women, and the feeling of use during eye drops was evaluated according to the following criteria. In addition, 14 ml of the test liquid was filled into a 15 ml container made of polyethylene terephthalate and having an eye drop of 1.0 mm in diameter, and the usability was examined. In the present invention, an average of 2.5 points or more is ◎, 2 to 2 points.
Less than 2.5 points were rated as ○, less than 1.5 to 2 points as Δ, and less than 1.5 points as x. (Test 3-1: Ease of dropping) 3 points Drip from the container is easy 2 points Dropping from the container is slightly slow / requires force to press the container 1 point Drip from the container is difficult (Test 3 2: sticky) 3 points: no stickiness 2 points: slightly sticky 1 point: sticky

[0035]

[Table 3]

[0036]

[Table 4]

[0037]

[Table 5]

In Tables 4 and 5, 1-menthol, dl
The following were used for camphor and d-borneol. l-menthol: Japanese Pharmacopoeia l-menthol (Takasago Perfumery Industry Co., Ltd., Toyo Usagi Kogyo Co., Ltd., Ogi Pharmaceutical Co., Ltd.),
dl-Camphor: Japanese Pharmacopoeia dl-Camphor (Takasago International Corporation, Ogi Pharmaceutical Co., Ltd.), d-borneol:
(Ogi Pharmaceutical Co., Ltd., Fujisawa Pharmaceutical Co., Ltd.)

In place of boric acid and borax in Tables 4 and 5, a composition comprising sodium hydrogen phosphate 1.5 and sodium dihydrogen phosphate 0.1, citric acid 0.01, sodium citrate 0.1. As a result of preparing and evaluating a composition which is 0.01 carbonic acid and 0.02 sodium bicarbonate, the interaction with mucin and the feeling of use of the composition as an eye drop show boric acid and borax. As good as when used, it was good.

Example 23 (Artificial tear-type eye drop) Hydroxypropyl methylcellulose (65SH-40)
0.3 g of 00 (manufactured by Shin-Etsu Chemical Co., Ltd.) and polyvinyl alcohol (EG-05 (manufactured by Nippon Synthetic Chemical Industry Co., Ltd.)
0.3 g, potassium hydrogen phosphate 1.2 g, sodium dihydrogen phosphate 0.22 g, polyoxyethylene (196)
0.1 g of polyoxypropylene (67) glycol, 1.0 g of aminoethylsulfonic acid, 0.25 g of potassium L-aspartate, 0.3 g of sodium chloride, 0.1 g of sodium edetate and 0.1 g of potassium sorbate
The solution is added to sterilized purified water heated to 0 ° C, mixed with stirring, and then rapidly cooled to 20 ° C or less. 0.003 g of 1-menthol previously dissolved in 0.2 g of propylene glycol, dl
-Add 0.005 g of camphor and 100 m with sterile purified water
L, sterilized by filtration, and aseptically filled in an eye drop container to give an artificial tear-type eye drop. This ophthalmic solution was evaluated not only with the naked eye but also with a hard contact lens and a soft contact lens in use, and as a result, a good feeling without discomfort (three evaluation points) was obtained. The score in Test 1 was 5 points.

Example 24 (Eyewash) 0.5 g of hydroxyethyl cellulose (SP-400 (Daicel Chemical Industries, Ltd.)) and polyvinyl alcohol (E)
G-05 (manufactured by Nippon Synthetic Chemical Industry Co., Ltd.) 0.2 g, boric acid 1.5 g, polyoxyethylene (20) sorbitan monooleate 0.2 g, cetylpyridinium chloride 0.0
8 g, pyridoxine hydrochloride 0.01 g, berberine chloride 0.0015 g, dipotassium glycyrrhizinate 0.02
5 g, chlorpheniramine maleate 0.003 g for 7
The solution is added to sterilized purified water heated to 0 ° C, mixed with stirring, and then rapidly cooled to 20 ° C or less. A solution prepared by dissolving 0.3 g of chlorobutanol, 0.03 g of l-menthol, and 0.01 g of dl-camphor in 1.0 g of propylene glycol in advance was dissolved in sterilized purified water to make a total volume of 100 mL, and filtered to prepare an eyewash. . Tests 1 and 3 have 4 points each,
3 points.

Example 25 (nasal drops) Hydroxypropyl methylcellulose (65SH-40)
00 (manufactured by Shin-Etsu Chemical Co., Ltd.) 2.0 g, polyvinyl alcohol (EG-05 (manufactured by Nippon Synthetic Chemical Industry Co., Ltd.)
2.0 g, citric acid 0.1 g, sodium citrate 0.
08g, polyoxyethylene hydrogenated castor oil 600.2
g, 0.1 g of tetrahydrozoline hydrochloride, 0.5 g of chlorpheniramine maleate, 0.5 g of lidocaine hydrochloride, and 0.02 g of benzalkonium chloride were added to sterilized purified water heated to 70 ° C., followed by stirring and mixing. Cool to below 20 ° C. The total amount was made up to 100 mL and filtered to give nasal drops. The score of Test 1 was 5 points.

Example 26 (Throat Remedy) 2.0 g of polyvinyl alcohol (EG-05 (manufactured by Nippon Synthetic Chemical Industry Co., Ltd.)) was added to sterilized purified water, stirred, mixed, and heated to 70 ° C. (SM
-50 (manufactured by Shin-Etsu Chemical Co., Ltd.), 1.0 g of sodium azulene sulfonate, 0.01 g of benzalkonium chloride and 0.3 g of sorbitan monooleate are stirred and mixed, and then cooled to 20 ° C. or lower. A solution prepared by dissolving 0.01 g of menthol in 1.0 g of propylene glycol in advance was added to make the total amount 100 ml, and the solution was filtered to obtain a throat therapeutic agent. The score of Test 1 was 5 points.

The component (B) used in the examples is the following water-soluble polymer. Methyl cellulose (Shin-Etsu Chemical Co., Ltd., Metroose SM) SM-15 (methoxyl group substitution rate 29.0%, molecular weight about 70,000) SM-25 (methoxyl group substitution rate 28.8%, molecular weight about 90,000) SM SM-50 (methoxyl group substitution rate 29.7%, molecular weight about 120,000) SM-100 (methoxyl group substitution rate 29.7%, molecular weight about 120,000) SM-100 (methoxyl group substitution rate 29.7%, molecular weight about 120,000) SM-1500 (methoxyl group substitution rate 29.6%, molecular weight about 290,000) SM-4000 (methoxyl group substitution rate 29.8%, molecular weight about 360,000)

Hydroxypropyl methylcellulose (manufactured by Shin-Etsu Chemical Co., Ltd., Metrose SH) 60SH-15 (alkoxyalkyl group substitution rate: 38.0%,
60SH-25 (alkoxyalkyl group substitution rate 37.8%,
60SH-50 (alkoxy group substitution rate 37.6%,
60SH-100 (alkoxy group substitution rate 37.9)
%, Molecular weight about 120,000) 60SH-400 (alkoxy group substitution rate 36.9)
%, Molecular weight about 170,000) 60SH-1500 (alkoxy group substitution rate 38.2)
%, Molecular weight about 290,000) 60SH-40-00 (alkoxy group substitution rate 38.
0%, molecular weight about 360,000)

Polyvinyl alcohol (Gosenol EG, KP, manufactured by Nippon Synthetic Chemical Industry Co., Ltd.) EG-05 (Saponification degree: 87.8 mol%, molecular weight: about 3)
EG-40 (Saponification degree: 87.7 mol%, molecular weight: about 11)
KP-08 (Saponification degree: 72.0 mol%, molecular weight: about 5)
Ten thousand)

──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. ⁷ Identification symbol FI theme coat ゛ (Reference) A61P 27/02 A61P 27/02 (72) Inventor Tsutomu Koide 1-3-7 Honjo, Sumida-ku, Tokyo No. Lion Corporation F term (reference) 4C076 AA12 AA94 BB21 BB24 CC03 CC04 CC10 CC22 DD01 DD21 DD22 DD37 EE06 EE08 EE23 EE31 EE32 EE37 FF31 FF61 4C086 AA02 BA08 GA02 MA03 MA05 MA17 MA58 NA12 ZA33 ZB13

Claims (7)

[Claims] (1) Drug (A) (B) Cellulosic polymer compound, saponification degree 78 mol
% Or more of a water-soluble polymer compound selected from polyvinyl alcohol which is not less than 10% by weight. (C) It contains a viscosity reducing agent if necessary, and has a viscosity at 20 ° C. of 1 mPas to 20 mPas,
Ophthalmic composition. 2. The ophthalmic composition according to claim 1, wherein the cellulosic polymer is a cellulose ether having a substitution ratio of hydroxyl groups of cellulose of 15 to 45% (in terms of the number of substituents). . (C) a surfactant and / or a compound having 2 to 2 carbon atoms.
The ophthalmic composition according to claim 1, wherein the composition is an alcohol. (4) a buffer (D): 0.01 to 10 W /
The ophthalmic composition according to any one of claims 1 to 3, comprising V%. 5. The ophthalmic composition according to claim 1, wherein the drug is at least one selected from an antiallergic agent, a decongestant, an antiinflammatory agent, and vitamins. (6) the drug is sodium cromoglycate,
Chlorpheniramine maleate, naphazoline hydrochloride, tetrahydrozoline hydrochloride, dipotassium glycyrrhizinate,
It is at least one selected from sodium azulene sulfonate, vitamins A, vitamin Es or derivatives thereof, pyridoxine hydrochloride, sodium flavin adenine dinucleotide, cyanocobalamin, and panthenol. Ophthalmic composition 7. A composition for improving retention of a drug on a living mucosa, comprising a cellulosic polymer compound and / or polyvinyl alcohol having a saponification degree of 78 mol% or more.